Mumbai-based Piramal Enterprises is continuing research and development work in Berlin on the PET (Positron Emission Tomography) technology it acquired from Bayer Healthcare earlier this year. The initiative wil lead to early detection of Alzheimer’s disease.
At a press briefing, Ajay Piramal, Chairman of the Piramal Group commented on the strategy, “Molecular imaging is one of the key technologies paving the way for individualized medicine. Our acquisition of a powerful pipeline in this field is an important milestone on the road to an innovative pharmaceutical portfolio.
Florbetaben, Piramal’s most advanced PET tracer, enables the detection of beta-amyloid deposits in the brain. “A phase III study to test the reliability of florbetaben in the histopathological detection of beta-amyloid has been successfully completed. Submission of the dossier for drug approval by the US Food and Drug Administration and the European Medicines Agency is expected later in 2012.
